Close
What would you like to look for?
Site search
Search filters

Memo Therapeutics AG Increases Series C Financing to CHF 45m

15 May 2024

Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing anti-body for BKV infection in kidney transplantation, raised CHF 20m as part of an extension of its series C financing round.

EraCal Therapeutics AG to license certain assets to Novo Nordisk

31 January 2024

EraCal Therapeutics AG ("EraCal"), a Swiss biotech start-up company focusing on the fight of obesity has licensed certain assets to Novo Nordisk for a total amount of EUR 235m in a collaboration and license deal.

GlycoEra AG increases its Series A Financing Round with investment by BMS

22 January 2024

GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional investment by Bristol Meyer Squibb (BMS).

Lallemand subsidiary Danstar Ferment AG takes over Evolva AG

4 January 2024

On 28 December 2023, Danstar Ferment AG, a Swiss subsidiary of Canadian multi-national, Lallemand Inc., has successfully completed the acquisition of Swiss based Evolva AG, subsidiary of SIX listed Evolva Holding SA.

Combination of Proteomedix and Blue Water Biotech to form Onconetix

20 December 2023

Proteomedix AG, ein privates Schweizer Diagnostikunternehmen im kommerziellen Stadium, und Blue Water Biotech, Inc.

Sale of T3 Pharmaceuticals AG to Boehringer Ingelheim

23 November 2023

T3 Pharmaceuticals AG, a biotechnology company with its headquarter in Allschwil, Switzerland has been acquired by Boehringer Ingelheim, a leading family-owned, research-driven biopharmaceutical company based in Ingelheim, Germany...

Nouscom Raises EUR 67.5m in Oversubscribed Series C Financing Round

14 November 2023

Nouscom AG, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today announced the completion of its oversubscribed Series C equity financing raising EUR 67.5m (USD 72m) from a syndicate of re-nowned international healthcare investors.

LASCCO and Abionic enter license agreement with Fapon

8 November 2023

LASCCO SA, a biomedical-technology company, and Abionic SA, a nanotechnology company, both based at the Biopôle of Lausanne, Switzerland, entered into a licensing agreement with Fapon Biotech, a global leading life sciences company, based in Dongguan, China, for the use of the pancreatic stone protein (PSP) biomarker for sepsis diagnosis in China.

Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients

7 November 2023

Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF25 million series C financing round led by Pureos Bioventures.

LimmaTech Biologics Raises USD 37m Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

12 October 2023

LimmaTech Biologics AG announced the closing of a USD 37m (CHF 33m) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.